Mitchell P. Fink, Professor
Chair, Department of Critical Care Medicine
MD, Washington University School of Medicine, St. Louis, MO, 1976
Email: finkmp@ccm.upmc.edu
Research Interest:
- Pathogensis of organ failure in sepsis.
- Cytokine-induced alterations in epithelial barrier function
- Development of novel therapeutic agents for sepsis.
- Sepsis-induced alterations in mitochondrial function.
Recent Publication
Macias CA, Chiao JW, Xiao J, Arora DS, Tyurina YY, Delude RL, Wipf P, Kagan VE, Fink MP. Treatment with a novel hemigramicidin-TEMPO conjugate prolongs survival in a rat model of lethal hemorrhagic shock. Ann Surg. 2007 Feb;245(2):305-14.
Jiang J, Kurnikov I, Belikova NA, Xiao J, Zhao Q, Amoscato AA, Braslau R, Studer A, Fink MP, Greenberger JS, Wipf P, Kagan VE. Structural requirements for optimized delivery, inhibition of oxidative stress, and antiapoptotic activity of targeted nitroxides. J Pharmacol Exp Ther. 2007 Mar;320(3):1050-60. Epub 2006 Dec 19.
Aneja R, Fink MP. Promising therapeutic agents for sepsis. Trends Microbiol. 2007 Jan;15(1):31-7. Epub 2006 Nov 21.
Lagoa CE, Bartels J, Baratt A, Tseng G, Clermont G, Fink MP, Billiar TR, Vodovotz Y. The role of initial trauma in the host's response to injury and hemorrhage: insights from a correlation of mathematical simulations and hepatic transcriptomic analysis.Shock. 2006 Dec;26(6):592-600.
Prince JM, Levy RM, Bartels J, Baratt A, Kane JM 3rd, Lagoa C, Rubin J, Day J, Wei J, Fink MP, Goyert SM, Clermont G, Billiar TR, Vodovotz Y. In silico and in vivo approach to elucidate the inflammatory complexity of CD14-deficient mice. Mol Med. 2006 Apr-Jun;12(4-6):88-96.
Yang R, Harada T, Mollen KP, Prince JM, Levy RM, Englert JA, Gallowitsch-Puerta M, Yang L, Yang H, Tracey KJ, Harbrecht BG, Billiar TR, Fink MP. Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med. 2006 Apr-Jun;12(4-6):105-14.
